Shares Held (Direct Ownership) 2.42M
5.44% 3M change
16.4% 12M change
Total Value Held N/A

Peter Blume-Jensen Transaction History

Date Transaction Value Shares Traded Shares Held Form
Aug 21 2024
SELL
Payment of exercise price or tax liability
$731,671 $9.19 p/Share
79,616 Reduced 3.18%
2,422,513 Common Stock
Aug 14 2024
SELL
Payment of exercise price or tax liability
$419,550 $7.02 p/Share
59,765 Reduced 2.33%
2,502,129 Common Stock
May 14 2024
SELL
Payment of exercise price or tax liability
$459,114 $8.36 p/Share
54,918 Reduced 2.1%
2,561,894 Common Stock
Feb 14 2024
SELL
Payment of exercise price or tax liability
$142,327 $3.4 p/Share
41,861 Reduced 1.57%
2,616,812 Common Stock
Nov 14 2023
SELL
Payment of exercise price or tax liability
$1,214,236 $5.08 p/Share
239,023 Reduced 8.25%
2,658,673 Common Stock
Aug 21 2023
BUY
Grant, award, or other acquisition
-
493,994 Added 14.56%
2,897,696 Common Stock
May 31 2023
BUY
Exercise of conversion of derivative security
$130,387 $3.88 p/Share
33,605 Added 1.38%
2,403,702 Common Stock
Nov 14 2022
BUY
Grant, award, or other acquisition
-
1,498,240 Added 38.73%
2,370,097 Common Stock
PB

Peter Blume Jensen

President and CEO
Watertown, MA

Track Institutional and Insider Activities on ACRV

Follow Acrivon Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ACRV shares.

Notify only if

Insider Trading

Get notified when an Acrivon Therapeutics, Inc. insider buys or sells ACRV shares.

Notify only if

News

Receive news related to Acrivon Therapeutics, Inc.

Track Activities on ACRV